MYND Life Sciences Inc. Stock OTC Markets
Equities
MYND.F
CA62857B1094
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0249 USD | +17.45% | -.--% | -20.19% |
Sales 2022 | - | Sales 2023 | - | Capitalization | 717K 984K |
---|---|---|---|---|---|
Net income 2022 | -3M -4.11M | Net income 2023 | -1M -1.37M | EV / Sales 2022 | - |
Net Debt 2022 | 2.59 3.55 | Net Debt 2023 | 3 4.11 | EV / Sales 2023 | - |
P/E ratio 2022 |
-1.05
x | P/E ratio 2023 |
-0.47
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 40.17% |
1 day | +17.45% | ||
3 months | +9.69% | ||
6 months | +24.50% | ||
Current year | -20.19% |
Managers | Title | Age | Since |
---|---|---|---|
John Campbell
CEO | Chief Executive Officer | 53 | 20-11-25 |
Lyle Oberg
FOU | Founder | 63 | 18-07-05 |
Founder | 65 | 18-07-05 |
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | 65 | 18-07-05 | |
Lyle Oberg
FOU | Founder | 63 | 18-07-05 |
John Campbell
CEO | Chief Executive Officer | 53 | 20-11-25 |
1st Jan change | Capi. | |
---|---|---|
+16.42% | 124B | |
+19.02% | 112B | |
+3.52% | 22.94B | |
-11.63% | 17.02B | |
-16.50% | 16.88B | |
-39.57% | 16.87B | |
+2.68% | 13.63B | |
+21.16% | 11.61B | |
+108.78% | 10.31B |
- Stock Market
- Equities
- MYND Stock
- MYND.F Stock